CAS 1638744-06-5

Formule : C25H29BrN8O2

InChI : InChI=1S/C25H29BrN8O2/c1-15(26)10-12-33-21-22(30-24(33)32-11-6-7-17(27)13-32)31(3)25(36)34(23(21)35)14-20-28-16(2)18-8-4-5-9-19(18)29-20/h4-5,8-10,17H,6-7,11-14,27H2,1-3H3/b15-10-/t17-/m1/s1

Code InChI : KOVUTSTYXMWMHQ-XBNGYDHASA-N

SMILES : CC1=NC(=NC2=CC=CC=C12)CN3C(=O)C4=C(N=C(N4C/C=C(/C)\Br)N5CCC[C@H](C5)N)N(C3=O)C

Linagliptin Related Compound D ((R,Z)-8-(3-Aminopiperidin-1-yl)-7-(3-bromobut-2-en-1-yl)-3-methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione)

CAS : 1638744-06-5

Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoi

Formule : C₂₅H₂₉BrN₈O₂

Couleur et forme : Light Yellow Powder

Masse moléculaire : 552.15968

Ref: 45-1366525

(R,Z)-8-(3-Aminopiperidin-1-yl)-7-(3-bromobut-2-en-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione

CAS : 1638744-06-5

(R,Z)-8-(3-Aminopiperidin-1-yl)-7-(3-bromobut-2-en-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione

Formule : C₂₅H₂₉BrN₈O₂

Degré de pureté : 96%

Masse moléculaire : 553.45

Ref: 54-OR1115119

(R,Z)-8-(3-Aminopiperidin-1-yl)-7-(3-bromobut-2-en-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-1H-purine-2,6-dione

CAS : 1638744-06-5

Formule : C₂₅H₂₉BrN₈O₂

Degré de pureté : 96%

Couleur et forme : Solid

Masse moléculaire : 553.4542

Ref: IN-DA00AQM5

Linagliptin EP Impurity D (Linagliptin USP Related Compound D)

CAS : 1638744-06-5

Formule : C₂₅H₂₉BrN₈O₂

Couleur et forme : Pale Yellow Solid

Masse moléculaire : 553.47

Ref: 4Z-L-4415

Linagliptin EP Impurity D

CAS : 1638744-06-5

Formule : C₂₅H₂₉BrN₈O₂

Masse moléculaire : 553.47

Ref: ST-EA-CP-L1017

N-Des-(2-butyn-1-yl)-N-(3-bromo-2-buten-1-yl) Linagliptin (E/Z Mixture)

CAS : 1446263-39-3, 1638744-06-5

Applications N-Des-(2-butyn-1-yl)-N-(3-bromo-2-buten-1-yl) Linagliptin is an impurity of Linagliptin (L465900); a novel potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor with potential use in the treatment of type 2 diabetes.
References Prabavathy, N. et al.: Int. J. Pharm. Bio. Sci., 2, 438 (2011); Deacon, C.F.: Diab. Obes. Metab., 13, 7 (2011)

Formule : C₂₅H₂₉BrN₈O₂

Couleur et forme : Neat

Masse moléculaire : 553.45

Ref: TR-D282015